Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update.

J Clin Oncol

Gary H. Lyman, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Stephen B. Edge, Baptist Cancer Center, Memphis, TN; Lisa A. Newman and James Hayman, University of Michigan, Ann Arbor, MI; Roderick R. Turner, John Wayne Cancer Institute, Santa Monica; Linda D. Bosserman, Wilshire Oncology Medical Group, Rancho Cucamonga; Armando E. Giuliano, Cedars-Sinai Medical Center, Los Angeles, CA; Donald L. Weaver, University of Vermont College of Medicine and Vermont Cancer Center, Burlington, VT; Al B. Benson III, Northwestern University, Chicago, IL; Harold J. Burstein, Dana-Farber Cancer Institute, Boston, MA; Hiram Cody III, Memorial Sloan Kettering Cancer Center, New York, NY; Cheryl L. Perkins, Patient Representative, Dallas; and Donald A. Podoloff, University of Texas MD Anderson Cancer Center, Houston, TX.

Published: May 2014

Purpose: To provide evidence-based recommendations to practicing oncologists, surgeons, and radiation therapy clinicians to update the 2005 clinical practice guideline on the use of sentinel node biopsy (SNB) for patients with early-stage breast cancer.

Methods: The American Society of Clinical Oncology convened an Update Committee of experts in medical oncology, pathology, radiation oncology, surgical oncology, guideline implementation, and advocacy. A systematic review of the literature was conducted from February 2004 to January 2013 in Medline. Guideline recommendations were based on the review of the evidence by Update Committee.

Results: This guideline update reflects changes in practice since the 2005 guideline. Nine randomized clinical trials (RCTs) met systematic review criteria for clinical questions 1 and 2; 13 cohort studies informed clinical question 3.

Recommendations: Women without sentinel lymph node (SLN) metastases should not receive axillary lymph node dissection (ALND). Women with one to two metastatic SLNs planning to undergo breast-conserving surgery with whole-breast radiotherapy should not undergo ALND (in most cases). Women with SLN metastases who will undergo mastectomy should be offered ALND. These three recommendation are based on RCTs. Women with operable breast cancer and multicentric tumors, with ductal carcinoma in situ (DCIS) who will undergo mastectomy, who previously underwent breast and/or axillary surgery, or who received preoperative/neoadjuvant systemic therapy may be offered SNB. Women who have large or locally advanced invasive breast cancer (tumor size T3/T4), inflammatory breast cancer, or DCIS (when breast-conserving surgery is planned) or are pregnant should not undergo SNB. These recommendations are based on cohort studies and/or informal consensus. In some cases, updated evidence was insufficient to update previous recommendations.

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.54.1177DOI Listing

Publication Analysis

Top Keywords

breast cancer
16
lymph node
12
sentinel lymph
8
node biopsy
8
patients early-stage
8
early-stage breast
8
american society
8
society clinical
8
clinical oncology
8
clinical practice
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!